34 Flashcards
Metabolic
Cancers curable with chemotherapy
Teratoma Seminoma High grade Hodgkin's lymphoma Wilm's Myeloma
Cancers with no gain for chemotherapy
Melanoma
Renal
Cholangiocarcinoma
MOA of cytotoxics
Antimetabolites: 5FU, gemcitabine, capectiabine
Alkylating agents: cyclophosphamide, cisplatin, carboplastin
Mitotic spindle poison: vincristine
Taxanes: paclitaxel, docetaxel
Modify tertiary structure of DNS: etoposide
Short term side effects of chemotherapy
Nausea and vomiting
Anorexia
Weight loss
Alopecia
Bone marrow suppression - neutropaenia, anaemia, thrombocytopaenia
Infective symptoms
Fatigue
Liver and renal toxicity
Mucositis
Peripheral sensory neuropathy
Ototoxcity
Acute cardiomyopathy
Long term side effects of chemotherapy
Cardiomyopathy
Pulmonary fibrosis
Increased risk of secondary cancers, particularly Hodgkin’s, acute leukaemia, testicular cancer
Subfertility/infertility
Renal insufficiency
Why are brain tumours hard to treat with chemotherapy
Chemotherapy is a large molecular with low solubility.
BBB is lipid soluble and small molecules.
Can’t cross the BBB to treat
Brain tumours also poorly irrigated.
When chemotherapy can be given?
Primary chemotherapy - sole anti cancer treatment if highly sensitive tumour types
Adjuvant - given after surgery to mop up microscopic disease
Neo-adjuvant - given pre-surgery to shrink the tumour
Concurrent - given with radiation
Hormonal chemotherapy therapies
Usually reserved for breast and prostate cancer.
Highly effective and relatively non-toxic.
Breast cancer:
- If oestrogen receptor positive, oestrogen binds to cells to increase growth
- Tamoxifen (SERM) competes for this binding to stop growth
- Aromatase inhibitors prevent precursors being converted into oestrogen
Prostate cancer:
- Androgens are a critical growth factor for prostate cancer
- Goserelin - LHRH agonist - reduces pituitary production of LH and FSH
- Flutamide anti-androgen, competitive androgen receptor inhibitor
Resistance will eventually develop
Biological chemotherapy agents
Work differently depending on the target cell.
Recognise and attach to specific proteins produced by cells.
- Breast cancer: Trastuzumab (Herceptin) if HER2 +
- Lymphoma: Rituximab (anti CD20)
- Colorectal cancer: Cetuximab (EGF receptor)
- Colorectal, lung and breast: bevactzumab (VEGF)
- CLL: Alemtuzumab (CD52)
- Lung cancer: Erlotinib (EGFR-TK mutation)
Insulin
Direct replacement for endogenous insulin
Subcutaneous
SE:
- Hypoglycaemia
- Weight gain
- Lipodystrophy
Used in all patients with T1DM and some patients with poorly controlled T2DM .
Can be classified according to source (analogue, human sequence and porcine) and duration of action (short, immediate, long-acting).
Metformin
Increases insulin sensitivity
Decreases hepatic gluconeogenesis
Oral
SE:
- Gastrointestinal upset
- Lactic acidosis*
First-line medication in the management of T2DM.
Cannot be used in patients with an eGFR of < 30 ml/min.
Sulfonylureas
Stimulate pancreatic beta cells to secrete insulin
Oral
SE:
- Hypoglycemia
- Weight gain
- Hyponatraemia
Examples include gliclazide and glimepiride
Thiazolidinediones
Activate PPAR-gamma receptor in adipocytes to promote adipogenesis and fatty acid uptake
Oral
SE:
- Weight gain
- Fluid retention
Only currently available thiazolidinedione is pioglitazone
DPP-4 inhibitors (-gliptins)
Increases incretin levels which inhibit glucagon secretion
Oral
Generally well tolerated but increased risk of pancreatitis
SGLT-2 inhibitors (-gliflozins)
Inhibits reabsorption of glucose in the kidney
Oral
SE:
- Urinary tract infection
Typically result in weight loss
GLP-1 agonists(-tides)
Incretin mimetic which inhibits glucagon secretion
Subcutaneous
SE:
- Nausea and vomiting
- Pancreatitis
Typically result in weight loss
ACTH stimulation test
Addison’s disease
Hyperkalaemia
- Acute renal failure
- Addison’s disease
- ACE inhibitors
- Spironolactone
- Metabolic acidosis
- Angiotensin 2 receptor blockers
- Massive blood transfusion
- Rhabdomyolysis
- Ciclosporin
- Renal tubular acidosis (type 4)
Hypernatraemia
- Diabetes insipidus
- Hyperosmolar non-ketotic diabetic coma
- Dehydration
Hyponatraemia
- SIADH
- Addison’s disease
- Vomiting
- Thiazides
- Liver cirrhosis
- Hypothyroidism
- Burns
- Heart failure
- Diarrhoea
- Psychogenic
- Polydipsia
What is paraneoplastic syndrome?
Paraneoplastic syndromes caused by renal cell carcinoma (RCC)?
When tumours act as ectopic endocrine organs resulting in over-secretion of hormones.
Paraneoplastic syndromes of RCC:
- EPO secretion (leads to polycythemia)
- Renin release (leads to hypertension)
- PTHrP* (leads to hypercalcaemia)
*Parathyroid hormone-related protein (PTHrP)
Breast cancer tumour marker
CA 15-3
Ovarian cancer tumour marker
CA 125